JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $911,000 | +323.7% | 20,305 | +78.1% | 0.02% | +283.3% |
| Q4 2016 | $215,000 | -5.7% | 11,400 | +120.2% | 0.01% | 0.0% |
| Q4 2015 | $228,000 | -31.9% | 5,176 | -17.6% | 0.01% | -40.0% |
| Q2 2015 | $335,000 | +33.5% | 6,282 | +52.0% | 0.01% | +25.0% |
| Q1 2015 | $251,000 | -92.1% | 4,133 | -93.2% | 0.01% | -92.7% |
| Q4 2014 | $3,166,000 | – | 60,631 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |